These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8658990)

  • 1. Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic.
    Armstrong DK; Convery A; Dinsmore WW
    Ulster Med J; 1994 Apr; 63(1):18-22. PubMed ID: 8658990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term safety of alprostadil (prostaglandin-E1) in patients with erectile dysfunction. The European Alprostadil Study Group.
    Br J Urol; 1998 Oct; 82(4):538-43. PubMed ID: 9806184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
    Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
    Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury.
    Earle CM; Keogh EJ; Ker JK; Cherry DJ; Tulloch AG; Lord DJ
    Paraplegia; 1992 Apr; 30(4):273-6. PubMed ID: 1625897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
    Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
    Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients].
    Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L
    Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians.
    Pangkahila WI
    Asian J Androl; 2000 Sep; 2(3):233-6. PubMed ID: 11225984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracavernous pharmacotherapy: comparison of Moxisylyte and prostaglandin E1.
    Buvat J; Lemaire A; Herbaut-Buvat M
    Int J Impot Res; 1996 Jun; 8(2):41-6. PubMed ID: 8858388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracavernous injection of prostaglandin E1 in spinal cord injured patients with erectile dysfunction. A preliminary report.
    Tang SF; Chu NK; Wong MK
    Paraplegia; 1995 Dec; 33(12):731-3. PubMed ID: 8927414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E1 in the therapy of erectile deficiency.
    Beretta G; Zanollo A; Ascani L; Re B
    Acta Eur Fertil; 1989; 20(5):305-8. PubMed ID: 2636808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Our experience with pharmacological erection treatment of erectile dysfunction.
    Hattat H; Ozkara H; Akkus E; Alici B
    J Androl; 1994; 15 Suppl():47S-49S. PubMed ID: 7721677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction.
    McMahon CG
    Int J Impot Res; 1996 Dec; 8(4):233-6. PubMed ID: 8981173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostaglandin E1 injection in erectile dysfunction. Current diagnostic and therapeutic possibilities].
    Schrey A
    Fortschr Med; 1990 Oct; 108(30):577-80. PubMed ID: 2245960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
    Valdevenito R; Melman A
    Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.
    Costabile RA; Spevak M; Fishman IJ; Govier FE; Hellstrom WJ; Shabsigh R; Nemo KJ; Rapport JL; Tam PY; Weldon KL; Gesundheit N
    J Urol; 1998 Oct; 160(4):1325-8. PubMed ID: 9751346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
    Loran OB; Segal AS; Shcheplev PA
    Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.